GE to Distribute Imaging Agent for Bladder Cancer

GE Healthcare (Chalfont St. Giles, UK) has exercised an exclusive option to license PhotoCure's (Oslo, Norway) product Hexvix (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer, for the US market.

This is an extension of the agreement signed earlier in 2006 that afforded GE Healthcare exclusive global rights outside of the Nordic region to market and distribute PhotoCure's product Hexvix. PhotoCure continues to be responsible for manufacturing and Nordic distribution of the product. This license, which is subject to government approval related to competition laws in the United States, grants GE the right to market and sell Hexvix in the United States pending U.S. Food and Drug Administration (FDA) approval of the drug for use.

"We believe our partnership with PhotoCure will result in significant patient benefit in the diagnosis and management of bladder cancer,” said Daniel L. Peters, president and CEO of Medical Diagnostics at GE Healthcare. "This partnership underscores GE Healthcare's commitment to addressing the unmet clinical needs of physician customers and to enhancing the quality of patient care through new approaches to the diagnosis and monitoring of disease.”



Related Links:
GE Healthcare
PhotoCure